Aortic acid

Aortic acid/Drug Interactions:

  • Antiangiogenic drugsAntiangiogenic drugs: Based on an animal study, aortic extract may inhibit vascularization (23).
  • AnticoagulantsAnticoagulants: Based on human studies, aortic acid may reduce the formation of blood clots (2; 3; 4; 5), and mesoglycan may regulate fibrinolysis (19; 20; 21).
  • Antidiabetic agentsAntidiabetic agents: Based on a clinical trial, mesoglycan may slightly lower serum glucose (27).
  • Antilipemic agentsAntilipemic agents: Based on human studies, aortic acid may lower total cholesterol and VLDL-triglyceride levels while raising HDL cholesterol and lipoprotein lipase activity (2; 3; 22; 11).
  • AntihypertensivesAntihypertensives: Based on a rat study, aortic extract, which contains arginine vasopressin, may produce pressor responses (9).
  • Antineoplastic agentsAntineoplastic agents: Based on animal and in vitro study, aortic extracts may inhibit the growth of tumors (24).
  • Cigarette smokeCigarette smoke: Based on an animal study, cigarette smoke may reduce the activity of aortic acid (25).
  • Fibrinolytic drugsFibrinolytic drugs: Based on human study, mesoglycan may decrease fibrinogen concentration (22) and regulate fibrinolysis (19; 20; 21).
  • Hormonal agentsHormonal agents: Based on an animal study, female sex hormones may affect aortic acid mucopolysaccharides' effect on atherosclerosis (18).
  • ImmunomodulatorsImmunomodulators: Based on an in vitro study, bovine aorta extract may exert significant dose-dependent inhibition of lymphocyte response (26).
  • Thyroid drugsThyroid drugs: Based on an animal study, thyroid drugs may affect aortic acid mucopolysaccharides' effect on atherosclerosis (28).
  • V1-receptor antagonistsV1-receptor antagonists: Based on a rat study, aortic acid may antagonize arginine vasopression V1 antagonists to blunt the hypotensive effect (9).

    • Aortic acid/Herb/Supplement Interactions:

  • AnticoagulantsAnticoagulants: Based on human studies, aortic acid may reduce the formation of blood clots (2; 3; 4; 5), and mesoglycan may regulate fibrinolysis (19; 20; 21).
  • AntilipemicsAntilipemics:: Based on human studies, aortic acid may lower total cholesterol and VLDL-triglyceride levels while raising HDL cholesterol and lipoprotein lipase activity (2; 3; 22; 11).
  • AntineoplasticsAntineoplastics: Based on animal and in vitro study, aortic extracts may inhibit the growth of tumors (24).
  • CopperCopper: Based on an animal study, copper deficiency may lead to an increase in aortic acid (29).
  • Estrogenic or progestin herbsEstrogenic or progestin herbs: Based on an animal study, female sex hormones may affect aortic acid mucopolysaccharides' effect on atherosclerosis (18).
  • HypoglycemicsHypoglycemics: Based on a clinical trial, mesoglycan may slightly lower serum glucose (27).
  • HypotensivesHypotensives: Based on a rat study, aortic extract may produce pressor responses that are significantly attenuated by pretreatment with a specific arginine vasopressin V1-receptor antagonist (9).
  • ImmunomodulatorsImmunomodulators: Based on an in vitro study, bovine aorta extract may exert significant dose-dependent inhibition of lymphocyte response (26).
  • Thyroid herbsThyroid herbs: Based on an animal study, thyroid drugs may affect aortic acid mucopolysaccharides' effect on atherosclerosis (28).
  • Vitamin CVitamin C: Based on an animal study, administration of vitamin C during copper deficiency may lead to an increase in aortic acid (29).

    • Aortic acid/Food Interactions:

  • Insufficient available evidence.

    • Aortic acid/Lab Interactions:

  • Alkaline phosphataseAlkaline phosphatase: Based on a clinical trial, mesoglycan may slightly influence alkaline phosphatase (27).
  • CholesterolCholesterol: Based on a clinical trial, mesoglycan may slightly influence cholesterol (27). However, based on other clinical studies, aortic acid may significantly lower total cholesterol and VLDL-triglyceride levels while raising HDL cholesterol and lipoprotein lipase activity (2; 3; 22; 11).
  • Coagulation panelCoagulation panel: Based on a clinical trial, mesoglycan may slightly influence coagulation time (27). However, in on other clinical studies, mesoglycan had a more pronounced effect on coagulation (2; 3; 4; 5).
  • CreatinineCreatinine: Based on a clinical trial, mesoglycan may slightly influence creatinine (27).
  • FibrinogenFibrinogen: Based on a clinical trial, mesoglycan may slightly influence fibrinogen (27). However, based on other clinical studies, fibrinogen plasma concentration may significantly decrease (22) or regulate fibrinolysis (19; 20; 21).
  • Glutamic oxalocetic transaminase (GOT)Glutamic oxalocetic transaminase (GOT): Based on a clinical trial, mesoglycan may slightly influence glutamic oxalocetic transaminase (27).
  • Glutamic pyruvic transaminaseGPT)Glutamic pyruvic transaminase (GPT): Based on a clinical trial, mesoglycan may slightly influence glutamic pyruvic transaminase (27).
  • Serum glucoseSerum glucose: Based on a clinical trial, mesoglycan may slightly influence serum glucose (27).
  • TriglyceridesTriglycerides: Based on a clinical trial, mesoglycan may slightly influence triglycerides (27). However, based on another clinical study, triglycerides may significantly decrease (22).
  • UreaUrea: Based on a clinical trial, mesoglycan may slightly influence urea (27).